Characteristics of Iranian Covid-19 clinical trials

Introduction and purpose:

Due to the widespread prevalence of Covid-19, Much effort has been made to find effective treatments, and clinical trial studies have increased. Therefore, this study aimed to determine the characteristics of Iranian Covid-19 clinical trial studies.

The study is applied research and has been done by the cross-sectional descriptive method. Data related to Iranian Covid-19 clinical trials were extracted from IRCT in February 2020, then examined in Excell Microsoft Office using descriptive statistic.

Until the data collection, 491 clinical trials associated with Covid-19 in IRCT were recorded, that a government organization supported 91.65%. An examination of the data indicates that 83.09% have used randomized assignment clinical trials. In 69.65% of clinical trials using a placebo, 50.1% of that blinding has not been done. 81.67% with the purpose of treatment done and 70.47% the intervention of clinical trials has been treatment-Drug.

the results of this study indicated a summary of the status and characteristics of clinical trials of Covid-19 recorded in IRCT. Given that the financial sponsor of most of these studies is Government Organization, It is recommended to use the financial resources of private pharmaceutical companies under the supervision and approval of the Food and Drug Administration to participate and support clinical trials.